The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENTA | -3.02% | -75.34% | -24.42% | -37% |
| S&P | +17.53% | +93.66% | +14.13% | +340% |
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.
The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.31M | 1.9% |
| Gross Profit | $17.10M | -1.6% |
| Gross Margin | 93.39% | -3.3% |
| Market Cap | $161.61M | -41.2% |
| Market Cap / Employee | $1.23M | 0.0% |
| Employees | 131 | 0.0% |
| Net Income | -$18.26M | 19.4% |
| EBITDA | -$17.68M | 25.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $44.81M | 23.2% |
| Accounts Receivable | $8.33M | 1.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $176.95M | -7.6% |
| Short Term Debt | $30.15M | -13.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.29% | -0.5% |
| Return On Invested Capital | -26.54% | -9.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $17.35M | 181.4% |
| Operating Free Cash Flow | $17.51M | 218.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.47 | 0.95 | 1.05 | 1.73 | 4.48% |
| Price to Sales | 3.25 | 1.83 | 1.83 | 2.49 | -34.68% |
| Price to Tangible Book Value | 1.47 | 0.95 | 1.05 | 1.73 | 4.48% |
| Enterprise Value to EBITDA | -6.70 | -5.57 | -6.03 | -9.31 | -18.73% |
| Return on Equity | -67.2% | -69.1% | -74.3% | -80.6% | 35.21% |
| Total Debt | $226.06M | $221.29M | $216.14M | $207.10M | -8.43% |
No podcast episodes available.
ENTA earnings call for the period ending June 30, 2022.
ENTA earnings call for the period ending March 31, 2022.
ENTA earnings call for the period ending December 31, 2021.
ENTA earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
